Genecraft is at the forefront of developing innovative gene therapy solutions aimed at improving treatment options for cancer patients, particularly those with K-RAS mutations. Their lead program, RX001, is a first-in-class treatment specifically designed to target and eliminate abnormal K-RAS mutated cancer cells while sparing normal cells. This selective approach is a significant advancement in oncology, as it leverages the innate oncogene defense system to transform the treatment paradigm for K-RAS mutated lung cancer. The company’s Ubi-AAV Platform further enhances its capabilities by enabling the crafting of gene contents into new gene therapeutics, thereby expanding the potential for effective cancer treatments.

The expertise of Genecraft's leadership team, which includes prominent researchers and industry veterans, underpins its commitment to pioneering gene therapy. With over 30 years of research experience in cancer treatment, the team is dedicated to addressing the challenges posed by previously incurable diseases through gene therapy technology. Their focus on the causal relationship between gene expression and disease underscores the belief that correcting genetic imbalances is essential for effective treatment strategies. By harnessing advanced gene therapy techniques, Genecraft aims to provide transformative solutions for patients facing life-threatening conditions.

South Korea

GeneCraft is a pre-clinical-stage biotech company dedicated to improving treatment and clinical outcomes for patients through gene therapy that harness the power of the immune system. The company's technology allows for the development of gene therapies for the treatment of cancer.

Cancer

Genetic Diseases

S19-102, 1, Chungdae-ro, Seowon-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea (Chungbuk National University)

Genecraft

Company Details